• TG Therapeutics recently raised its total revenue guidance for 2026 after reporting stronger-than-expected sales of Briumvi, its approved therapy for relapsing forms of multiple sclerosis.
• The company is also running multiple clinical studies aimed at broadening Briumvi’s indications and improving how it is administered, which could reshape its longer-term product profile.
• We’ll now examine how the upgraded 2026 revenue guidance tied to Briumvi’s performance could influence TG Therapeutics’ existing investment narrative.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

TG Therapeutics Investment Narrative Recap

To own TG Therapeutics, you need to be comfortable with a story built almost entirely around Briumvi and its continued commercial traction in multiple sclerosis. The raised 2026 revenue guidance reinforces Briumvi as the key near term catalyst, but it also magnifies the central risk that any slowdown in uptake, pricing, or payer support could have an outsized impact on results.

The recent completion of enrollment in the Phase 3 trial of subcutaneous Briumvi is especially relevant here, as it directly targets the payer and patient preference shift toward self administered therapies. How that readout ultimately lines up against TG’s upgraded revenue targets will be important for assessing whether Briumvi can extend its reach without worsening exposure to pricing pressure.

Yet investors should also be aware that if payer pushback on high cost specialty drugs intensifies, especially around self administered MS therapies, then...

TG Therapeutics' narrative projects $1.5 billion revenue and $461.7 million earnings by 2029.

Uncover how TG Therapeutics' forecasts yield a $44.43 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenue could reach about US$1.5 billion by 2028, but if payer driven pricing pressure on Briumvi accelerates, your view on that upside may differ significantly from theirs.

Explore 7 other fair value estimates on TG Therapeutics - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your TG Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TG Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 46 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.